Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914307 | 1.00 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL10015775 | 1.00 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL6577627 | 0.87 | POLB (0.58) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL12836955 | 0.87 | POLB (0.66) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL12352409 | 0.87 | POLB (0.66) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL14639913 | 0.87 | POLB (0.66) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL30712246 | 0.86 | POLB (0.58) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL10015785 | 0.86 | POLB (0.46) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL27375710 | 0.86 | POLB (0.46) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL27375503 | 0.86 | POLB (0.46) | POLBSTING1PDE3BPDE3APNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | POLB 52/4885STING1 267/4885PDE3B 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.